Evidence map›Paper›PMID 30904992›Full record

ArticleInternational journal of hematology2019

First case of neutropenia and thrombocytopenia in the setting of cerebral cavernous malformation 3.

Clay Travis Cohen, Katie Lee Bergstrom, Rui Xiao, Mohamed Tarek Elghetany, Ionela Iacobas, Ghadir Sasa

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in International journal of hematology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. The multifacetedGenes & diseases · 2021
    Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Clay Travis CohenDepartment of Pediatrics, Section of Hematology-Oncology, Texas Children's Cancer and Hematology Center, Baylor College of Medicine, Texas Children's Hospital, 1102 Bates St. Ste. C1025, Houston, TX, 77030, USA. ctcohen@texaschildrens.org.ORCID http://orcid.org/0000-0001-6819-4049
Katie Lee BergstromDepartment of Pediatrics, Section of Hematology-Oncology, Texas Children's Cancer and Hematology Center, Baylor College of Medicine, Texas Children's Hospital, 1102 Bates St. Ste. C1025, Houston, TX, 77030, USA.
Rui XiaoDepartment of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA.
Mohamed Tarek ElghetanyDepartment of Pathology and Immunology, Baylor College of Medicine, Texas Children's Hospital, Houston, TX, USA.
Ionela IacobasDepartment of Pediatrics, Section of Hematology-Oncology, Texas Children's Cancer and Hematology Center, Baylor College of Medicine, Texas Children's Hospital, 1102 Bates St. Ste. C1025, Houston, TX, 77030, USA.
Ghadir SasaDepartment of Pediatrics, Section of Hematology-Oncology, Texas Children's Cancer and Hematology Center, Baylor College of Medicine, Texas Children's Hospital, 1102 Bates St. Ste. C1025, Houston, TX, 77030, USA.
Baylor College of Medicine · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cerebral cavernous malformation 3 (CCM3) is a vascular malformation disorder causing brain slow-flow vascular parenchymal lesions. These lesions are the result of variants in the Programmed Cell Death Protein 10 (PDCD10) gene, located on 3q26.1. We report an 8-month-old patient who was presented with seizures and intracranial abscesses and was found to have a variant of PDCD10 on whole exome sequencing, representing, to our knowledge, the youngest case of CCM3 described in the literature. Her clinical course was complicated by the development of neutropenia, requiring granulocyte colony-stimulating factor, and thrombocytopenia, requiring intermittent platelet transfusions, with later development of B acute lymphoblastic leukemia 2 years after initial presentation. This case represents the first description in the literature of hematologic complications in the setting of CCM3. We hypothesize that these hematological manifestations are the result of alterations in the actin and microtubule cytoskeleton, affecting the process of hematopoiesis in a similar fashion to the documented effect of the PDCD10 variant on neuronal migration.

Indexed as

Apoptosis Regulatory ProteinsCentral Nervous System NeoplasmsFemaleGenetic VariationHemangioma, Cavernous, Central Nervous SystemHematopoiesisHumansInfantMembrane ProteinsNeutropeniaPrecursor B-Cell Lymphoblastic Leukemia-LymphomaProto-Oncogene ProteinsThrombocytopeniaApoptosis Regulatory ProteinsMembrane ProteinsPDCD10 protein, humanProto-Oncogene ProteinsCerebral cavernous malformation 3NeutropeniaPancytopeniaThrombocytopeniaVascular malformation

Identifiers

PMID30904992
OpenAlexW2937835773

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.